Bortez 2mg Injection

Bortezomib is an antineoplastic drug available for intravenous (IV) and subcutaneous injection. It acts as a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex responsible for degrading ubiquitinated proteins, crucial for regulating specific intracellular proteins and maintaining cellular homeostasis. Inhibition of this pathway disrupts normal cellular processes and can lead to cell death. Studies have shown that Bortezomib is cytotoxic to various cancer cell types and delays tumor growth in models of multiple myeloma.
The distribution volume of Bortezomib at the recommended dose in patients with multiple myeloma has not been assessed. The average binding of Bortezomib to human plasma proteins is 83% within the concentration range of 100–1000 ng/mL.

Bortezomib is primarily metabolized via cytochrome P450 enzymes (3A4, 2C19, and 1A2), with minor metabolism through CYP 2D6 and 2C9. The major metabolic route involves deboronation, resulting in two de-boronated metabolites, which are inactive as proteasome inhibitors.
The mean elimination half-life of Bortezomib ranges from 9 to 15 hours, with doses between 1.45 and 2.00 mg/m2 in patients with advanced cancers. The elimination pathways of Bortezomib in humans have not been fully characterized.